3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow Intermediate Risk Acute Myeloid Leukemia: new trials by email Literature Review of Intermediate Risk Acute Myeloid Leukemia trials Research Report on Intermediate Risk Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VA Consolidation in Intermediate-Risk AML Venetoclax and Azacitidine, Cytarabine ± Anthracycline - Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 226 | 2026-06-01 | 2026-08-06 |
| Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML GVA + HDAC Consolidation & Gilteritinib Maintenance - Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 25 | 2026-01-25 | 2026-02-04 |
| Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients venetoclax, azacitidine and HAAG regimen - Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 60 | 2024-02-15 | 2024-05-01 |
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Azacitidine (2) · venetoclax (2)
The First Affiliated Hospital of Soochow University (2) · First Affiliated Hospital of Zhejiang University (1)
China (3)